Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: Comparisons of volume-based metabolic parameters

Head and Neck

Volumn 35, Issue 1, 2013, Pages 15-22

  Moon, Seung Hwan ^a   Choi, Joon Young ^a   Lee, Hwan Joo ^a   Son, Young Ik ^a   Baek, Chung Hwan ^a   Ahn, Yong Chan ^a   Park, Keunchil ^a   Lee, Kyung Han ^a   Kim, Byung Tae ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

18F FDG; metabolic tumor volume; PET CT; prognosis prediction; SUV; tonsil cancer; total lesion glycolysis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; FEMALE; GLYCOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TONSIL CARCINOMA; TUMOR VOLUME; AGED; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEAD AND NECK TUMOR; METHODOLOGY; MIDDLE AGED; PALATINE TONSIL; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; SURVIVAL; TONSIL TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PALATINE TONSIL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; SURVIVAL ANALYSIS; TONSILLAR NEOPLASMS;

EID: 84871204699     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.22904     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Guay ME, Lavertu P,. Tonsillar carcinoma. Eur Arch Otorhinolaryngol 1995; 252: 259-264.
3. St Guily JL, Clavel C, Okaïs C, et al. Human papillomavirus genotype distribution in tonsil cancers. Head Neck Oncol 2011; 3:Art. 6.
4. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML,. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612-619. (Pubitemid 351264356)
5. Scully C, Bagan JV,. Recent advances in oral oncology 2008; squamous cell carcinoma imaging, treatment, prognostication and treatment outcomes. Oral Oncol 2009; 45: e25-e30.
6. Patel SG, Shah JP,. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 2005; 55: 242-258; quiz, 261-262, 264. (Pubitemid 41271230)
7. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 2007; 69: 328-333. (Pubitemid 47380105)
8. 18F-FDG PET in oncology. J Nucl Med 2008; 49: 480-508. (Pubitemid 351355215)
9. Kubicek GJ, Champ C, Fogh S, et al. FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol 2010; 2:Art. 19.
10. Wax MK, Myers LL, Gabalski EC, Husain S, Gona JM, Nabi H,. Positron emission tomography in the evaluation of synchronous lung lesions in patients with untreated head and neck cancer. Arch Otolaryngol Head Neck Surg 2002; 128: 703-707. (Pubitemid 34665855)
11. 18F]-2- fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope 2005; 115: 1186-1190. (Pubitemid 40962353)
12. 18F- fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol 2007; 18: 1698-1703. (Pubitemid 47506258)
13. 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med 2005; 46: 405-410. (Pubitemid 43093147)
14. Murakami R, Uozumi H, Hirai T, et al. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007; 68: 377-382. (Pubitemid 46694156)
15. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004; 130: 1361-1367. (Pubitemid 39603296)
16. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002; 24: 127-135. (Pubitemid 34111509)
17. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997; 38: 1907-1911. (Pubitemid 28030920)
18. 18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004; 59: 1295-1300. (Pubitemid 38954050)
19. Greven KM, Williams DW III, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001; 23: 942-946. (Pubitemid 32977536)
20. 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 2010; 17: 115-122.
21. 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2010; 136: 883-889.
22. Leibold T, Akhurst TJ, Chessin DB, et al. Evaluation of (18)F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis. Ann Surg Oncol 2011; 18: 2783-2789.
23. La TH, Filion EJ, Turnbull BB, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1335-1341.
24. 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinomas treated by surgery. Nucl Med Mol Imaging 2011; 45: 43-51.
25. Kim BS, Kim IJ, Kim SJ, et al. The prognostic value of the metabolic tumor volume in FIGO stage IA to IIB cervical cancer for tumor recurrence: measured by F-18 FDG PET/CT. Nucl Med Mol Imaging 2011; 45: 36-42.
26. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med 2009; 50: 340-347.
27. Lee HY, Hyun SH, Lee KS, et al. Volume-based parameter of (18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 2010; 17: 2787-2794.
28. Meng X, Sun X, Mu D, et al. Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 2007: 1-7.
29. Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C,. Prognostic value of (18)F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging 2011; 38: 1191-1202.
30. 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. AJR Am J Roentgenol 2009; 192: 745-753.
31. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578. (Pubitemid 350002965)
32. Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging 2011; 38: 1064-1071.
33. 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 2005; 46: 1342-1348. (Pubitemid 43733485)
34. Heagerty PJ, Lumley T, Pepe MS,. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56: 337-344. (Pubitemid 30422619)
35. Zheng Y, Cai T, Feng Z,. Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers. Biometrics 2006; 62: 279-287.
36. van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM,. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000; 117: 374-379. (Pubitemid 30111585)
37. Takes RP, Rinaldo A, Silver CE, et al. Future of the TNM classification and staging system in head and neck cancer. Head Neck 2010; 32: 1693-1711.
38. Prestwich RJ, Kancherla K, Oksuz DC, et al. A single centre experience with sequential and concomitant chemoradiotherapy in locally advanced stage IV tonsillar cancer. Radiat Oncol 2010; 5: 121 (abstract).
39. Lee SW, Nam SY, Im KC, et al. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy- D -glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008; 87: 211-216.
40. 18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23: 1136-1143. (Pubitemid 46202269)
41. Soret M, Bacharach SL, Buvat I,. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48: 932-945. (Pubitemid 46909922)
42. Murphy JD, La TH, Chu K, et al. Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010; 80: 514-521.
43. Kawabe J, Okamura T, Shakudo M, et al. Physiological FDG uptake in the palatine tonsils. Ann Nucl Med 2001; 15: 297-300. (Pubitemid 32679230)
44. Davison JM, Ozonoff A, Imsande HM, Grillone GA, Subramaniam RM,. Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake. Radiology 2010; 255: 578-585.
45. Yildirim G, Morrison WH, Rosenthal DI, et al. Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapy. Head Neck 2010; 32: 473-480.
46. Genden EM, Ferlito A, Scully C, Shaha AR, Higgins K, Rinaldo A,. Current management of tonsillar cancer. Oral Oncol 2003; 39: 337-342. (Pubitemid 36379340)